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Network Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USAThe kidney is inﬂuenced by circadian rhythms and is
entrained to the sleep-wake cycle allowing anticipation of
the metabolic and physiological demands of the kidney
throughout a 24-hour cycle. Although sleep disruption has
been studied extensively in cardiovascular and metabolic
disease, its association with chronic kidney disease has not
been shown. We examined this in a prospective cohort
study of 4238 participants from the Nurses’ Health Study
and analyzed the association of self-reported sleep
duration with decline in renal function over an 11-year
period (1989 to 2000). Individuals who reported shorter
sleep duration were more likely to experience a rapid
decline in estimated glomerular ﬁltration rate (30% or
more). Compared with sleeping 7 to 8 hours per night, the
adjusted odds ratios for a rapid decline in renal function
were a signiﬁcant 1.79 (95% CI, 1.06–3.03) for 5 hours or
less sleep per night, a signiﬁcant 1.31 (95% CI, 1.01–1.71)
for 6 hours sleep per night, but an insigniﬁcant 0.88
(95% CI, 0.50–1.57) for 9 or more hours sleep per night.
Similarly, there was a signiﬁcant trend in the adjusted
annualized decline in estimated glomerular ﬁltration rate
of 1.2 ml/min/1.73 m2/year, 0.9 ml/min/1.73 m2/year,
0.8 ml/min/1.73 m2/year, and 0.8 ml/min/1.73 m2/year for
individuals sleeping 5 hours or less per night, 6 hours
per night, 7 to 8 hours per night, and 9 hours or more
per night, respectively. Thus, shorter sleep duration is
prospectively and independently associated with faster
decline in renal function.
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1324M ost renal physiologic processes follow a diurnalrhythm, including regulation of the renin-angiotensin system, sodium reabsorption, renal
blood ﬂow, glomerular ﬁltration, and ﬁltration fraction; simi-
larly, 13% of gene transcription in the kidney is diurnal.1–6
Coordination of the circadian periodicity of these processes
allows the kidney to anticipate changes in metabolic and
physiological demands throughout a 24-hour cycle. However,
changes to lifestyle and work practices have diminished the
amount of nightly sleep many people obtain, thereby altering
the times at which workers are required to be awake and
desynchronizing basic physiologic rhythms from environ-
mental demands.
There is growing evidence that changes in sleep duration
and time of sleep onset may have detrimental effects on renal
function. Short sleep duration and shift work are associated
with risk factors for chronic kidney disease (CKD), including
hypertension, diabetes, and cardiovascular disease.7–9 As
examples, individuals who report sleeping 5 hours or less per
night are 20% more likely to develop hypertension,7 34%
more likely to develop diabetes,8 and 45% more likely to
develop cardiovascular disease9 compared with those sleeping
7 hours per night. A variety of cross-sectional studies have
found that patients with kidney disease have shorter average
sleep durations overall,10 and in a single prospective study of
6834 Japanese adults, those who slept 6 or fewer hours per
night were 70% more likely to develop proteinuria than were
individuals who slept for 7 hours per night.11 However, a
prospective association between sleep duration and decline in
renal function has not been demonstrated. Thus, we per-
formed a prospective analysis among participants of the
Nurse’s Health Study with self-reported sleep duration
ascertained at baseline and renal function measured at 2 or
more time points during an 11-year follow-up.RESULTS
Participant baseline characteristics
There were 4238 women in the Nurse’s Health Study with
serum creatinine measured in 1989 and again in 2000. In
1989, the mean age was 58.0 years (6.6 years), mean body
mass index was 25.8 kg/m2 (5.1 kg/m2), and the mean
estimated glomerular ﬁltration rate (eGFR) was 88.3 ml/min/
1.73 m2 (25.0 ml/min/1.73 m2). Overall, 9.7% of women
were diabetic, 28.7% had a history of hypertension, and 3.8%
had a history of cardiovascular disease (Table 1). Median sleep
duration was 7 hours (6–8 hours, 25th–75th percentile).Kidney International (2016) 89, 1324–1330
Table 1 | Comparison of baseline covariates across categories of sleep duration in NHS I with serum Cr measured in 1989
and 2000
Covariate
All
(N [ 4238)
Category of sleep duration (reported in 1986)
P valuea
£5 hrs
(n [ 157)
6 hrs
(n [ 1007)
7–8 hrs
(n [ 2882)
‡9 hrs
(n [ 192)
Mean ± SD
Age (yrs) 58.0  6.6 57.7  6.3 57.6  6.6 58.1  6.5 58.7  7.1 0.08
eGFRb (ml/min/1.73 m2) 88.3  25.0 89.5  20.6 89.9  37.4 87.8  19.5 86.8  19.1 0.11
SBP (mm Hg) 127  14 130  15 128  14 127  13 129  14 0.08
BMI (kg/m2) 25.8  5.1 27.8  6.3 26.3  5.5 25.5  4.9 26.2  5.7 <0.001
Activity (METS/week) 16.7  21.5 15.0  19.1 16.0  19.0 17.2  22.7 14.8  16.4 0.16
n (%)
Smoking history
Current 502 (11.9) 23 (14.7) 130 (12.9) 323 (11.2) 27 (13.5) 0.32
Previous 1744 (41.2) 55 (35.0) 406 (40.4) 1193 (41.5) 90 (46.9)
Never 1983 (46.8) 79 (50.3) 468 (46.5) 1360 (47.2) 76 (39.6)
Missing 9 (0.2) 0 (0) 3 (0.3) 6 (0.2) 0 (0)
History of
Diabetes 410 (9.7) 20 (12.7) 110 (10.9) 252 (8.7) 28 (14.6) 0.009
Hypertension 1214 (28.7) 53 (33.8) 314 (31.2) 781 (27.1) 66 (34.4) 0.01
Cardiovascular disease 164 (3.8) 10 (6.3) 53 (5.2) 91 (3.1) 10 (5.2) 0.005
Hypercholesterolemia 1828 (43.1) 69 (44.0) 454 (45.1) 1218 (42.3) 87 (45.3) 0.41
NSAID use in 1990c 992 (27.7) 38 (28.2) 258 (30.0) 643 (26.5) 53 (32.7) 0.10
NSAID use in 2000c 934 (22.0) 29 (18.5) 229 (22.7) 632 (21.9) 44 (22.9) 0.67
Acetaminophen usec 672 (18.7) 31 (23.0) 175 20.2) 442 (18.3) 24 (14.9) 0.19
ACEI use in 1988 108 (2.5) 3 (1.9) 31 (3.1) 70 (2.4) 4 (2.1) 0.63
ACEI use in 2000 579 (13.7) 17 (10.8) 156 (15.5) 379 (13.2) 27 (14.1) 0.20
ACEI, angiotensin-converting enzyme inhibitor; BMI, body mass index; DASH, Dietary Approaches to Stop Hypertension; eGFR, estimated glomerular ﬁltration rate; MDRD,
Modiﬁcation of Diet in Renal Disease Study; METS, metabolic equivalents; NHS, Nurse’s Health Study; NSAID, Nonsteroidal anti-inﬂammatory drug; SBP, systolic blood pressure.
aP values are calculated using analysis of variance test for continuous variables and chi-square for categorical variables.
beGFR was calculated using the MDRD equation.
cNSAID and acetaminophen use more than once per week.
CJ McMullan et al.: Short sleep duration and decline in renal function c l i n i ca l i nves t iga t ionIndividuals who reported sleeping 5 or fewer hours per night
had a higher mean body mass index and higher prevalences of
diabetes, hypertension, and cardiovascular disease at baseline
compared with those who reported sleeping 7 to 8 hours per
night. Age, baseline eGFR, snoring patterns, and use of
nonsteroidal anti-inﬂammatory drugs (NSAIDs), acetamino-
phen, and angiotensin-converting enzyme inhibitors (ACEI)
were all similar across categories of sleep duration. The most
frequent self-reported sleep duration was 7 to 8 hours per
night in 2882 individuals, with 157 individuals reporting 5 or
fewer hours per night, 1007 reporting 6 hours per night, and
192 reporting 9 or more hours per night.
Association of baseline sleep duration with eGFR decline
Rapid decline in renal function was observed in 529 in-
dividuals (12%), whereas the mean annualized decline in
eGFR for the cohort was 1.0 ml/min/1.73 m2 (2.2 ml/min/
1.73 m2). The mean eGFR in those with rapid decline was
103.5 ml/min/1.73 m2 at baseline (1989), which decreased to
59.3 ml/min/1.73 m2 at follow-up (2000). Of the 529 subjects
who developed rapid decline in renal function, 288 (54%)
developed CKD stage 3 or higher.
Compared with participants who reported 7 to 8 hours of
sleep per night, the age adjusted odds ratios (ORs) for
experiencing a rapid decline in renal function were 1.91 (95%
conﬁdence interval [CI], 1.27–2.88, P ¼ 0.002) among par-
ticipants who reported 5 or fewer hours of sleep per nightKidney International (2016) 89, 1324–1330and 1.30 (95% CI, 1.05–1.60, P ¼ 0.01) among participants
reporting 6 hours per night. After adjustment for age, sys-
tolic blood pressure, body mass index, eGFR, smoking status
(current, previous, never), history of hypertension, history
of diabetes, history of hypercholesterolemia, use of acet-
aminophen at baseline, use of medications that reversibly
effect eGFR at baseline and follow-up (ACEI in 1988, and in
2000, and use of NSAIDs in 1990, and in 2000), the corre-
sponding ORs for experiencing a rapid decline in renal
function were 1.79 (95% CI, 1.06–3.03, P ¼ 0.03) for par-
ticipants who reported 5 or fewer hours of sleep per night
and 1.31 (95% CI, 1.01–1.71, P ¼ 0.04) for participants who
reported 6 hours of sleep per night (P value for linear trend
across categories of sleep duration 0.005) (Table 2). Further
adjustment for shift work did not materially alter the results
(OR ¼ 1.75, 95% CI, 1.04–2.96 comparing #5 hours with 7–
8 hours; P ¼ 0.04). For 4063 individuals with normal baseline
renal function, the fully adjusted OR of incident CKD at
follow-up was 1.95 (95% CI, 1.16–3.30, P ¼ 0.01) among
participants who reported 5 or fewer hours of sleep per night
and 1.18 (95% CI, 0.90–1.54, P ¼ 0.24) among participants
reporting 6 hours of sleep per night compared with those who
reported 7 to 8 hours of sleep per night (P ¼ 0.02 for trend of
increased CKD risk with shorter sleep duration)
(Supplementary Table S1).
Individuals in the reference group, 7 to 8 hours per night,
had the slowest rate of decline in renal function, with an1325
Table 2 | Odds ratio of eGFR decrease of ‡30% between 1989 and 2000 by category of sleep duration
Category of
sleep duration
(reported in 1986)
Number of
individuals
Number of events
(eGFR decrease ‡30%)
Mean eGFR
decline (±SD)
Odds ratio (95% CI)
Age adjusted P values Fully adjusteda P values P trend
#5 hrs 157 31 13.8  22.6 1.91 (1.27–2.88) 0.002 1.79 (1.06–3.03) 0.03 0.005
6 hrs 1007 144 12.4  37.8 1.30 (1.05–1.60) 0.01 1.31 (1.01–1.71) 0.04
7–8 hrs 2882 331 9.9  18.1 1.00 Reference 1.00 Reference
$9 hrs 192 23 10.0  16.2 1.04 (0.66–1.63) 0.88 0.88 (0.50–1.57) 0.67
ACEI, angiotensin-converting enzyme inhibitor; eGFR, estimated glomerular ﬁltration rate; NSAID, Nonsteroidal anti-inﬂammatory drug.
aAdjusted for age, systolic blood pressure, body mass index, baseline eGFR, history of diabetes, history of cardiovascular disease, history of hypercholesterolemia, history of
hypertension, acetaminophen use, ACEI use (1988 and 2000), NSAID use (1990 and 2000), and smoking status (current, previous, never).
c l i n i ca l i nves t iga t i on CJ McMullan et al.: Short sleep duration and decline in renal functionannualized eGFR decline of 0.9 ml/min/1.73 m2/year (1.7
ml/min/1.73 m2/year). This was signiﬁcantly slower than the
rate of decline for those who reported 6 hours per night
(annualized eGFR decline of 1.1  3.4 ml/min/1.73 m2/year,
P ¼ 0.009). Women who reported sleeping 5 hours or less per
night had the most rapid rate of decline in renal function
(annualized eGFR decline of 1.3  2 ml/min/1.73 m2/year),
which was not statistically different from the decline in the
reference group (P ¼ 0.07). These annualized eGFR decline
rates remained virtually unchanged with age and multivari-
able adjustment, and there was a signiﬁcant trend toward
faster renal function decline with decreased sleep duration
(adjusted P trend ¼ 0.008) (Table 3).
Association of baseline sleep duration with albuminuria
A total of 3489 individuals from the Nurse’s Health Study
who returned urine samples in 2000 had urine albumin
and creatinine measured (urine samples were unavailable in
1989). Albuminuria in 2000 was twice as prevalent among
individuals who, in 1986, reported sleeping 5 or fewer
hours per night than those who reported 7 to 8 hours per
night (adjusted OR ¼ 2.52; 95% CI, 1.42–4.49, P ¼ 0.002)
with a signiﬁcant trend toward increased prevalence of
albuminuria with shorter sleep duration in multivariable
models (P trend ¼ 0.002) (Supplementary Table S2).
Sensitivity analyses
In a sensitivity analysis, we expanded our analysis to include
all women (n ¼ 4268) with serum creatinine measurement
available in 1989 and again either in 2000, 2003, or 2007. We
included all 17,072 eGFR measures to model eGFRTable 3 | Average annualized change in eGFR from 1989 to 2000
Category of
sleep duration
(reported in 1986)
Number of
individuals
Age adjusted
Annualized eGFR
change (±SD)
(ml/min/1.73 m2/yr)
#5 hrs 157 1.3  0.2
6 hrs 1007 1.1  0.1
7–8 hrs 2882 0.9  0.1
$9 hrs 192 0.9  0.2
ACEI, angiotensin-converting enzyme inhibitor; eGFR, estimated glomerular ﬁltration ra
aAdjusted for age, systolic blood pressure, body mass index, eGFR, history of diabetes,
tension, acetaminophen use, ACEI use (1988 and 2000), NSAID use (1990 and 2000), an
1326trajectories using linear mixed effects regression employing
random intercepts and slopes (Table 4). In age and multi-
variable adjusted analyses, shorter sleep duration was signif-
icantly associated with eGFR decline (adjusted P value for the
group effect of sleep duration ¼ 0.002). In adjusted models,
sleeping 6 hours per night was associated with a 30% faster
decline in eGFR relative to sleeping 7 to 8 hours per night
(P < 0.001).
In other sensitivity analyses, we repeated our primary
analysis, measuring the association of sleep duration with
rapid decline in renal function, with additional adjustment
for incident hypertension, incident diabetes, and incident
cardiovascular disease occurring during the follow-up period.
In these analyses, the association of shorter sleep duration
with rapid decline in renal function remained signiﬁcant
(P value for linear trend# 0.007) (Supplementary Tables S3–5).
Finally, replacing the KDIGO (Kidney Disease: Improving
Global Outcomes) deﬁnition of albuminuria with sex-speciﬁc
deﬁnitions did not signiﬁcantly change the association of
shorter sleep duration in 1986 with a greater prevalence of
albuminuria in 2000 (P value for linear trend ¼ 0.02).DISCUSSION
In this large prospective study of middle-aged women with
11 years of follow-up, shorter sleep duration was signiﬁcantly
and independently associated with a more rapid decline in
renal function. To our knowledge, this is the ﬁrst prospective
study to ﬁnd that shorter sleep duration is associated with a
more rapid decline in eGFR.
Nearly all human data examining the association of sleep
and CKD come from cross-sectional, rather than prospectiveby category of sleep duration
Fully adjusteda
P trendP value
Annualized eGFR
change (±SD)
(ml/min/1.73 m2/yr) P value
0.05 1.2  0.1 0.01 0.008
0.005 0.9  0.1 0.10
Reference 0.8  0.1 Reference
0.99 0.8  0.1 0.81
te; NSAID, Nonsteroidal anti-inﬂammatory drug.
history of cardiovascular disease, history of hypercholesterolemia, history of hyper-
d smoking status (current, previous, never).
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Table 4 | Mixed effects model for average annualized change in eGFR, including all eGFR measurements
Category of
sleep duration
(reported in 1986)
Number of
individuals
Age adjusted Fully adjusteda
Annualized
eGFR change
(ml/min/1.73 m2/yr) P value
P value for
group effect of
sleep duration
Annualized
eGFR change
(ml/min/1.73 m2/yr) P value
P value for
group effect of
sleep duration
#5 hrs 159 1.0 0.27 0.002 1.0 0.44 0.004
6 hrs 1014 1.1 0.0002 1.1 0.0004
7–8 hrs 2901 0.9 Reference 0.9 Reference
$9 hrs 194 0.8 0.77 0.8 0.55
ACEI, angiotensin-converting enzyme inhibitor; eGFR, estimated glomerular ﬁltration rate; NSAID, Nonsteroidal anti-inﬂammatory drug.
aAdjusted for age, systolic blood pressure, body mass index, history of diabetes, history of cardiovascular disease, history of hypercholesterolemia, history of hypertension,
acetaminophen use at baseline, ACEI and NSAID use as time varying covariates and smoking status (current, previous, never).
CJ McMullan et al.: Short sleep duration and decline in renal function c l i n i ca l i nves t iga t ionstudies. Patients with advanced CKD have a higher prevalence
of several sleep disturbances, including reversal of day-night
sleep pattern, increased sleep latency, and fragmented sleep
related to sleep apnea or restless leg syndrome.10 A small
study, for example, found that shorter sleep duration (i.e., <5
hours per night measured by actigraphy) was signiﬁcantly
more prevalent among individuals with non-dialysis-
dependent CKD (31%) and end-stage renal disease (53%)
as compared with those with normal renal function (11%).12
Another study that employed polysomnography reported
increased sleep fragmentation and decreased rapid eye
movement sleep in patients with end-stage renal disease
compared with those who had non-dialysis-dependent
CKD.13 It is most commonly argued that this relation is
mediated by uremic toxins, volume overload, and depression
as possible mechanisms, each of which can accompany
advanced CKD.10 In contrast, the potential importance of
circadian disruption as a risk factor preceding the develop-
ment of CKD has received considerably less attention.
Although animal data suggest that circadian disruption
may induce kidney damage, prospective human data on the
association of sleep factors with incident kidney disease are
scarce. In animals, genetic disruption of circadian rhythms
produce characteristics of CKD including elevated serum
creatinine, glomerular and tubular damage, and ﬁbrotic
changes in the cortex, all of which are preventable by strictly
controlling light-dark periodicity to restore circadian
rhythms.14 In humans, only 2 longitudinal analyses of in-
dividuals without CKD have studied the association of sleep
duration with changes in renal parameters. The ﬁrst, a study
of 6834 Japanese adults, found that those who slept 6 or fewer
hours per night were 1.7 times more likely to develop pro-
teinuria at 4 years than individuals who slept for 7 to 8 hours
per night; changes in eGFR were not reported.11 Although we
lacked information about albuminuria at baseline, the ﬁnd-
ings of our secondary analysis of albuminuria at 11 years were
consistent with this Japanese study. The second, substantially
smaller prospective study of 463 adults found that the
adjusted risk of a 10-year decline in eGFR of >3% was 0.83
(95% CI, 0.64–1.08) per additional hour of sleep per night;
this potential beneﬁt from additional sleep (or, reciprocally, a
determent from less sleep) was not statistically signiﬁcant,
possibly due low statistical power.15 Consistent with theirKidney International (2016) 89, 1324–1330observations, we found that shorter sleep duration was
signiﬁcantly and independently associated with faster annu-
alized decline in eGFR and a greater risk of having a $30%
decline in eGFR at 11 years.
The mechanisms underlying a potential association of
sleep with incidence of decline in renal function need to be
elucidated. Sleep disturbances, such as habitual sleep restric-
tion, may predispose to incident CKD by increasing the risk
of developing established CKD risk factors. As an example,
individuals who report sleeping 5 or fewer hours per night are
20% more likely to develop hypertension and 57% more
likely to develop incident diabetes during a 10-year period
than are those sleeping 7 hours per night.7,8 In short-term
studies lasting 3 to 6 weeks, shortening or lengthening the
time slept by healthy individuals increased or decreased in-
sulin resistance and blood pressure, further suggesting that
sleep duration is a modiﬁable determinant of these estab-
lished CKD risk factors.16–18 However, in our cohort,
adjusting for development of incident hypertension, diabetes,
or cardiovascular disease did not materially change effect
estimates for the risk of developing rapid renal function
decline with shorter sleep duration. This suggests that either
short sleep duration is associated with more rapid decline in
renal function via a mechanism independent of these estab-
lished CKD risk factors or, alternatively, these endpoints did
not fully capture the metabolic and vascular consequences of
short sleep.
Our study has limitations. First sleep duration was self-
reported with potential for misclassiﬁcation. Self-reported
or perceived sleep time often differs from objectively
measured sleep using polysomnography or wrist actigraphy.
In a study of 669 individuals, for example, sleep duration was
measured both objectively using wrist actigraphy and sub-
jectively with a sleep questionnaire.19 In that study, those with
objectively short sleep duration subjectively overestimated
their sleep duration. Speciﬁcally, those with objective sleep
measured as 5 hours per night overestimated sleep by
1.3 hours (i.e., self-reported 6.3 hours of sleep). In contrast,
those with objective sleep measured as 7 hours per night more
accurately self-reported their sleep duration (i.e., the differ-
ence was only 0.3 hours).19 If this ﬁnding is applicable to our
study, then the distribution of sleep duration in our popu-
lation may be narrower than the true distribution, which1327
c l i n i ca l i nves t iga t i on CJ McMullan et al.: Short sleep duration and decline in renal functionwould have made it more difﬁcult to detect an association
rather than ﬁnd a spurious association. Second, information
on sleep duration was collected in 1986, 3 years prior to the
initial eGFR measurement. However, there is likely a
reasonably good correlation between usual sleep duration
separated by 3 years among healthy middle-aged women. As
examples, the intraclass correlation coefﬁcient (ICC) for sleep
duration reported on the 1986 and 2000 questionnaires was
0.41, whereas over the shorter, 6-year period from 2002 to
2008, the ICC was 0.53. Thus, it is likely that the correlation
over 3 years in this population would be similar or better.
Nevertheless, the resulting misclassiﬁcation of sleep duration
would tend to produce an association that actually un-
derestimates, rather than overestimates, the true association.
Third, only 2 measures of eGFR were used in the primary
analysis, and therefore if either eGFR measurement was
transiently altered due other factors, the calculated eGFR
decline from 1989 to 2000 will not accurately reﬂect the true
underlying longitudinal eGFR change during that period.
However, this was a relatively healthy population at low risk
for developing acute kidney injury, and we controlled for use
of ACEI and NSAIDs, which would be the most likely factors
that could reversibly change the eGFR. In addition, our sec-
ondary analysis using mixed effects regression to incorporate
all available eGFR values was consistent with ﬁndings from
our primary analysis. Fourth, albuminuria was not measured
at baseline because urine was not collected in 1989; therefore,
we could not analyze the association of sleep duration with
change in urinary albumin secretion, nor could we adjust for
albuminuria in the primary analysis. However, our ﬁndings
that shorter sleep duration was associated with the presence of
albuminuria in 2000 is consistent with another large study
that reported short sleep duration was a risk factor for inci-
dent proteinuria.11 Fifth, the number of individuals reporting
sleep duration of 9 hours or greater was limited and so we
were unable to assess whether there was a U-shaped associ-
ation between sleep duration and more rapid decline in renal
function (a U-shaped association was found between sleep
duration and both diabetes and mortality).8,9 Sixth, our study
population was limited to women, and most participants were
white. Thus, it is unknown whether our ﬁndings can be
applied to men and to other racial groups. Seventh, in this
observational study, many of the baseline covariates used in
the analyses were self-reported on biennial questionnaires;
potential misreporting of this information could produce
residual confounding. However, the validity of this
questionnaire-based information has been demonstrated.
Finally, as with all observational studies, we cannot exclude
the possibility that our ﬁndings are confounded by factors
that we could not ascertain.
In conclusion, we have found a robust association between
shorter sleep duration and a more rapid decline in renal
function that was independent of many established CKD risk
factors. Further studies, including those using more accurate
measurements of sleep, are required to conﬁrm these ﬁnd-
ings, and to elucidate potential mechanisms mediating1328this association, with a view toward potential therapeutic
interventions.
METHODS
Study design and study participants
The Nurses’ Health Study20 began in 1976 when 121,700 registered
nurses ages 30 to 55 years returned an initial questionnaire. On this
and subsequent biennial questionnaires, health status, medications,
dietary intake, and lifestyle factors including smoking history,
physical activity, and sleeping patterns were ascertained. In addition
to completing questionnaires, blood samples were provided by
subpopulations of these women in 1989 and 2000. First morning
urine samples were provided in 2000. Between 1989 and 1990,
32,826 participants provided blood samples that were shipped with a
cold pack by overnight mail, whereupon they were aliquoted and
stored in liquid nitrogen until the time they were assayed. In 2000,
18,720 of these participants submitted a second blood sample and
spot urine sample under the same handling conditions. Two addi-
tional blood samples were collected in 2003 and 2007 as part of a
substudy of analgesic use and renal function. Serum creatinine was
measured in 9163 participants in 1989, 5187 participants in 2000,
2000 participants in 2003, and 1750 participants in 2007. Of those
participants with information on sleep duration from the 1986
questionnaire, 4238 had serum creatinine measured in 1989 and
again in 2000. These individuals made up the population for the
primary analysis. In a sensitivity analysis, we included all 4268
women who had serum creatinine measured in 1989 and at least
once during the 2000, 2003, or 2007 blood collections.
All women in this cohort provided implied consent by virtue of
voluntarily returning mailed questionnaires and by voluntarily
providing blood and urine samples via mailed collection kits. The
institutional review board at Brigham and Women’s Hospital
approved this study.
Sleep duration
Sleep duration was reported on the 1986 biennial questionnaire as
the total number per 24 hours that the participant slept. For the
purpose of this analysis, sleep duration was categorized into 5 or
fewer hours, 6 hours, 7 to 8 hours, and 9 or more hours per
24 hours. Sleep duration was also asked on several other question-
naires. The ICC for sleep duration reported in the 1986 and
2000 questionnaires was 0.41 and was 0.53 between 2002 and 2008,
suggesting moderate stability of sleep duration in these nurses during
the follow-up period used in the primary analysis.
Renal function
Plasma creatinine was measured using a modiﬁed Jaffe reaction
(coefﬁcient of variation [CV], 10%). eGFR was estimated from
plasma creatinine using the 4-variable Modiﬁcation of Diet in Renal
Disease (MDRD) Study equation. Rapid decline in renal function
was deﬁned as a decrease in eGFR $ 30% from 1989 to 2000 and
was the primary endpoint.21 The annualized rate of eGFR decline
between 1989 and 2000 was a secondary endpoint, as was develop-
ment of incident chronic kidney disease deﬁned as eGFR # 60
ml/min/1.73 m2.22
Urinary measurements were performed on spot urine samples
obtained from the 2000 collection. Urinary albumin was measured
by a solid phase ﬂuorescence immunoassay using the Hitachi
911 analyzer (Roche, Basel, Switzerland) and Roche diagnostic
reagents with a lower limit of detection of 0.1 mg/ml (CV, 8.0%).Kidney International (2016) 89, 1324–1330
CJ McMullan et al.: Short sleep duration and decline in renal function c l i n i ca l i nves t iga t ionUrinary creatinine was measured using a modiﬁed Jaffe reaction (CV,
1.6%). Albuminuria was deﬁned using the KDIGO guidelines as
urinary albumin to creatinine ratio $30 mg/g.23 In a sensitivity
analysis, albuminuria was deﬁned using a sex-speciﬁc deﬁnition of
albuminuria (albumin to creatinine ratio $ 25 mg/g for women,
which has been proposed by several groups).24–26
Other covariates
Age, self-reported race, and menopausal status, as well as body mass
index (kilograms of body weight divided by the squared height in
meters), systolic blood pressure, history of cardiovascular disease
(angina, myocardial infarction, coronary artery bypass, or stroke),
diabetes, hypertension, hypercholesterolemia, and smoking status
(current, past, never) were determined from a questionnaire
completed at the time of urine and blood sample submission.
Frequency of medication use was also available from questionnaires
in 1990 and 2000, and from these we determined the frequency of
use of NSAIDs and acetaminophen, with frequent use categorized as
taking these medications more than once per week. Also the use of
ACEIs was available from the 1988 and 2000 questionnaires.
Statistical analysis
Distributions of covariates were examined by category of self-
reported sleep duration (#5 hours, 6 hours, 7–8 hours, $9 hours
per 24 hours). The means and frequencies for all covariates were
compared with analysis of variance or chi-squared testing between
categories of self-reported sleep duration.
The change in eGFR from 1989 to 2000 was calculated for each
individual. In the primary analysis, logistic regression was used to
examine the association of rapid decline in renal function with the
category of baseline sleep duration, using the most populous cate-
gory, 7 to 8 hours per night, as the reference. Models were adjusted
for established risk factors for CKD (age [continuous], systolic blood
pressure [continuous], body mass index [continuous], history of
cardiovascular disease [yes/no], diabetes [yes/no], hypertension
[yes/no], hypercholesterolemia [yes/no], smoking status [current/
previous/never], and acetaminophen use [$1 per week, which is
associated with renal function decline in this cohort]).27,28 In addi-
tion, we controlled for factors that could have hemodynamic effects
on eGFR (ACEI use at baseline [yes/no], ACEI use at follow-up
[yes/no], NSAID use at baseline [$1 per week], and NSAID use at
follow-up [$1 per week]). Hosmer and Lemeshow goodness-of-ﬁt
test was performed to ensure logistic regression models were
appropriate. An additional analysis was performed in which the
number of years that a participant worked rotating night shifts was
included in the multivariable models. A secondary analysis was
performed using multivariable linear regression to examine the
association of sleep duration with annualized rate of eGFR decline
from 1989 to 2000. The association of sleep duration in 1986 and the
presence of albuminuria in 2000 was examined with multivariable
logistic regression, adjusting for predictors of CKD. Lastly, among
4063 individuals with normal renal function at baseline, eGFR
$ 60 ml/min/1.73 m2, multivariable logistic regression was used to
examine the association of incident CKD with category of baseline
sleep duration.
In a sensitivity analysis of repeated measures, the association of
baseline sleep duration with decline in eGFR was examined using
linear mixed effects analysis; this analysis included all available
measurements of serum creatinine from 1989 to 2007 in women
with serum creatinine measured on at least 2 occasions. We assumed
random intercepts and slopes to model eGFR over time; theKidney International (2016) 89, 1324–1330interaction term of sleep category with time was used to assess for an
association of sleep duration with annualized eGFR decline. This
model was adjusted for the same covariates included in the primary
multivariable model we discussed earlier. In another sensitivity
analysis, we repeated our primary analysis after excluding all 1214
individuals with baseline hypertension. Lastly, we repeated the
analysis of the association of sleep duration and presence of albu-
minuria with albuminuria measured using a sex-speciﬁc cut-off
(i.e., albumin to creatinine ratio $25 mg/g).
All analyses were performed with SAS statistical software (Cary,
NC). Two-tailed P < 0.05 was considered statistically signiﬁcant.
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